Alex Dahmani

Alex Dahmani

Company: Adaptive Biotech

Job title: Director, Business Development


Monitoring Infused Treg Cells in vivo to Predict Response, Remission and Relapse 10:00 am

Cell therapy outcomes in oncology have shown that a durable response is associated with persistence of the infusion product in vivo Adaptive’s highly-sensitive immune sequencing technology characterizes the full TCR repertoire of the infusion product The endogenous TCR can be used to track infused Treg clones in vivo in order to measure persistence and predict…Read more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.